Article: Terazosin

Terazosin
Systematic (IUPAC) name
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl) piperazin-1-yl]- tetrahydrofuran-2-yl-methanone
Identifiers
CAS number	63590-64-7
ATC code	G04CA03
PubChem	5401
DrugBank	APRD00667
Chemical data
Formula	C19H25N5O4
Mol. weight	387.433 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	90-94%
Metabolism	?
Half life	12 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Terazosin (Hytrin®) is an alpha blocker used for treatment of symptoms of prostate enlargement (BPH). It also acts to lower the blood pressure, so is a drug of choice for men with hypertension and prostate enlargement.

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Sexual side effects are rare, but may include priapism or erectile dysfunction.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.